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Figure 2. (a) pYSTAT1 high cells are more
resistant to ionizing radiation. (b) pYSTAT1
activation is correlated with resistance to ionizing
radiation.
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Methods
Hypothesis 
Figure 1. pY-STAT1/3 levels in 12 HNSCC lines: UM-SCC-
17B selected for STAT3/1 CRISPR KO.
Results 
• Activation of IFN/STAT1 pathway correlated with
resistance to ionizing radiation (Pearson R: 0.9150, p =
0.0294) of HNSCC cell lines
• Ability of TTI-101, the dual STAT3/1 inhibitor to inhibit
cell-growth correlated with its ability to inhibit pY-STAT3
in these cells (Pearson R: 0.8354, p = 0.0014)
• Co-treatment with 3 µM of TTI-101 sensitized the chemo-
resistant line HN31 to platinum-based chemotherapy
drugs cisplatin (IC50 shift from 14 µM to 0.01 µM),
carboplatin (IC50 shift from 163.4 µM to 0.04 µM) and
oxaliplatin (IC50 shift from 15.7 µM to 2.9 µM) through
successful reduction of pY-STAT3 (IC50 ~7µM), indicating
the role of activated STAT3 in HNSCC cell
chemoresistance
• Beta-tubulin-normalized tSTAT3 protein levels via
Luminex showed successful STAT3-CRISPR-KO ROC2
clones (p<0.05)
• STAT3-KO ROC2 cells proliferated in 2% serum at lower
rates than control cells validating that STAT3 augments
cell-growth of HNSCC tumor cells
Background
• Signal Transducers and Activators of Transcription 3 (STAT3) has
been validated as a target in head and neck squamous cell
carcinoma (HNSCC)1,2
• 37-75% of HNSCC tumor samples and correlated with more
advanced disease stage, tumor size, and lower survival1
• Activated STAT1 has also been correlated with radio-resistance2,3
• TTI-101, the dual STAT3 and STAT1 inhibitor, inhibited growth of
xenografts of pY-STAT3-high, pY-STAT1-high chemo and
radioresistant cell line UM-SCC-17B by successfully reducing
both pY-STAT3 and pY-STAT1 levels and downregulating
oncogenic gene1
• Role of STAT1 and STAT3 in cell-growth and radioresistance by
suing knockouts (KOs) has not been clearly delineated
pYSTAT1 and pYSTAT3 inhibition in HNSCC
• IC50 of inhibition of constitutive pY-STAT1 and pY-STAT3 in 12
HNSCC cell lines by TTI-101 the dual STAT3/STAT1 inhibitor was
estimated using bead-based Luminex assay
Platinum-based chemotherapy and radiation
• Sensitivity of HNSCC lines to fixed ionized radiation dosage was
estimated using clonogenic assays
• TTI-101 sensitization of HN31 to cisplatin, oxaliplatin, carboplatin
platinum-based chemotherapy drugs by MTT
CRISPR STAT1, STAT3, STAT1/3 KO
• gRNA CRISPR transfection of mice HNSCC cells ROC1, ROC2
and human UM-SCC-17B was done and single clones with
validated KOs (protein, Luminex) were selected
• Clones selected from pools, tSTAT3 and STAT1 KO’s validated
by Luminex. Measurements of beta-normalized values were
plotted for various cell lines
MTT proliferation assay
• Effect of TTI-101 on cell growth of human HNSCC cell lines
(IC50) and STAT3 KO on ROC2 cells (Fold change over day zero
after 24, 48, 96, and 144 hours, in 2% FBS media) were
measured by MTT
HNSCC cells























































































































































































































































































































































Figure 5. (a) Luminex validation of tSTAT3 levels in CRISPR controls and CRISPR KO Roc2 HNSCC lines (p
< 0.05) (b) STAT3 CRISPR KO reduces anchorage dependent growth of ROC2 cells under low serum
conditions.
Treatment
Growth Inhibition (IC50, μM)
HN30 
(sensitive) HN31 (resistant)
C188-9 4.2 ± 0.07 4.0 ± 0.14
CDDP 11.1 ± 0.07 14.8 ± 0.64
CDDP + C9 (3.0 μM) 1.1 ± 1.55 0.01 ± 0.00
CDDP + C9 (10.0 μM) 13.4 ± 18.9 0.01 ± 0.00
CBP 89.4 ± 3.11 163.4 ± 4.95
CBP + C9 (3.0 μM) NA 0.04 ± 0.01
CBP + C9 (10.0 μM) 0.30 ± 0.14 0.06 ± 0.01
OXP 4.85 ± 29.56 15.70 ± 1.84
OXP + C9 (3.0 μM) 0.08 ± 0.08 2.95 ±1.06
OXP + C9 (10.0 μM) 0.42 ± 0.54 0.002 ±0.00
b.a.
Figure 6. TTI-101 treatment sensitized chemo-resistant line
HN31 to platinum-based chemotherapy drugs cisplatin
(CDDP), carboplatin (CBP), oxaliplatin (OXP).




The data indicates a role of activated STAT3 in growth and
chemoresistance in HNSCC mice and human cell lines,
while indicating the role of activated STAT1 in
radioresistance. Ongoing work to assess the effects of
STAT1, STAT3 double KO in HNSCC cell growth and
susceptibility to chemo and radiotherapy is needed to
delineate the independent or synergistic effects of their
activation.
HNSC  cells






















































































































































































































































































































Pearson R: 0.8354 (p = 0.0014)
Spearman R: 0.8182 (p = 0.0033)
IC50-pSTAT1-IC50-growth corelation
11 HNSCC


















Figure 3. (a) pYSTAT1 levels are not
significantly correlated with growth inhibition.
(b) Growth inhibition correlates to pYSTAT3
inhibition in UM-SCC-17B cells.
Pearson R: 0.3533 (p = 0.0865)
Spearman R: 0.3768(p = 0.2509)
Figure 4. Roc2 beta-
normalized pYSTAT3 and
tSTAT3 levels. High constitutive
pYSTAT3 expression was seen
in Roc1, Roc2 cells was
exhibited; selection of Roc1 and
Roc2 as HNSCC lines for
tSTAT3 CRISPR KO’s. Roc2
exhibited highest constitutive
pYSTAT3 activation.
• STAT3 supports growth and chemoresistance while
activates STAT1 leads to radioresistance in HNSCC
tumor cells
a.
b.
